Search Results

There are 5045 results for: content related to: Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

  1. You have free access to this content
    Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

    Hepatology

    Volume 62, Issue 3, September 2015, Pages: 932–954, AASLD/IDSA HCV Guidance Panel

    Article first published online : 4 AUG 2015, DOI: 10.1002/hep.27950

  2. You have free access to this content
    Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 714A–807A,

    Article first published online : 7 OCT 2015, DOI: 10.1002/hep.28228

  3. You have full text access to this OnlineOpen article
    Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

    Hepatology

    Volume 61, Issue 4, April 2015, Pages: 1174–1182, Nikolien van de Ven, Joe Fortunak, Bryony Simmons, Nathan Ford, Graham S. Cooke, Saye Khoo and Andrew Hill

    Article first published online : 9 FEB 2015, DOI: 10.1002/hep.27641

  4. You have free access to this content
    Poster Session 2: Hepatitis C: Approved Therapeutic Agents

    Hepatology

    Volume 60, Issue S1, October 2014, Pages: 659A–709A,

    Article first published online : 1 OCT 2014, DOI: 10.1002/hep.27516

  5. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials

    Hepatology

    Volume 61, Issue 6, June 2015, Pages: 1798–1808, Zobair M. Younossi, Maria Stepanova, Patrick Marcellin, Nezam Afdhal, Kris V. Kowdley, Stefan Zeuzem and Sharon L. Hunt

    Article first published online : 18 MAR 2015, DOI: 10.1002/hep.27724

  6. You have free access to this content
    Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

    Hepatology

    Volume 60, Issue 1, July 2014, Pages: 37–45, Liesl M. Hagan, Mark S. Sulkowski and Raymond F. Schinazi

    Article first published online : 14 MAY 2014, DOI: 10.1002/hep.27151

  7. You have free access to this content
    Poster Sessions

    Hepatology

    Volume 60, Issue S1, October 2014, Pages: 92A–196A,

    Article first published online : 1 OCT 2014, DOI: 10.1002/hep.27415

  8. Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection

    Hepatology

    Volume 62, Issue 4, October 2015, Pages: 1047–1058, Aaron F. Carlin, Paula Aristizabal, Qinghua Song, Huan Wang, Matthew S. Paulson, Luisa M. Stamm, Robert T. Schooley and David L. Wyles

    Article first published online : 22 AUG 2015, DOI: 10.1002/hep.27971

  9. You have full text access to this OnlineOpen article
    Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

    Hepatology

    Volume 61, Issue 3, March 2015, Pages: 769–775, Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory-Sobol, William T. Symonds, John G. McHutchison and Fernando E. Membreno

    Article first published online : 30 JAN 2015, DOI: 10.1002/hep.27567

  10. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1–infected patients

    Hepatology

    Volume 61, Issue 3, March 2015, Pages: 790–801, Eric G. Meissner, Yu-Jin Lee, Anu Osinusi, Zayani Sims, Jing Qin, Dan Sturdevant, John McHutchison, Mani Subramanian, Maureen Sampson, Susanna Naggie, Keyur Patel, Alan T. Remaley, Henry Masur and Shyam Kottilil

    Article first published online : 28 JAN 2015, DOI: 10.1002/hep.27424

  11. You have free access to this content
    Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin

    Hepatology

    Volume 61, Issue 2, February 2015, Pages: 471–480, Charlotte Hedskog, Brian Doehle, Krishna Chodavarapu, Viktoria Gontcharova, Javier Crespo Garcia, Robert De Knegt, Joost P.H Drenth, John G. McHutchison, Diana Brainard, Luisa M. Stamm, Michael D. Miller, Evguenia Svarovskaia and Hongmei Mo

    Article first published online : 15 DEC 2014, DOI: 10.1002/hep.27361

  12. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

    Hepatology

    Volume 62, Issue 4, October 2015, Pages: 1004–1012, Bashar A. Aqel, Surakit Pungpapong, Michael Leise, K. Tuesday Werner, Amy E. Chervenak, Kymberly D. Watt, Jennifer L. Murphy, Kristen Ryland, Andrew P. Keaveny, Ryan McLemore and Hugo E. Vargas

    Article first published online : 7 AUG 2015, DOI: 10.1002/hep.27937

  13. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States

    Hepatology

    Volume 61, Issue 5, May 2015, Pages: 1471–1478, Zobair M. Younossi, Yushan Jiang, Nathaniel J. Smith, Maria Stepanova and Rachel Beckerman

    Article first published online : 23 MAR 2015, DOI: 10.1002/hep.27757

  14. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant

    Hepatology

    Volume 61, Issue 6, June 2015, Pages: 1880–1886, Surakit Pungpapong, Bashar Aqel, Michael Leise, K. Tuesday Werner, Jennifer L. Murphy, Tanisha M. Henry, Kristen Ryland, Amy E. Chervenak, Kymberly D. Watt, Hugo E. Vargas and Andrew P. Keaveny

    Article first published online : 27 APR 2015, DOI: 10.1002/hep.27770

  15. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection

    Hepatology

    Volume 63, Issue 2, February 2016, Pages: 634–643, Travis B. Dick, Lance S. Lindberg, Debra D. Ramirez and Michael R. Charlton

    Article first published online : 21 SEP 2015, DOI: 10.1002/hep.27920

  16. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

    Hepatology

    Volume 62, Issue 4, October 2015, Pages: 1013–1023, Jean-Michel Pawlotsky, Robert Flisiak, Shiv K. Sarin, Jens Rasenack, Teerha Piratvisuth, Wan-Long Chuang, Cheng-Yuan Peng, Graham R. Foster, Samir Shah, Heiner Wedemeyer, Christophe Hézode, Wei Zhang, Kelly A. Wong, Bin Li, Claudio Avila, Nikolai V. Naoumov and on behalf of the VITAL-1 study team

    Article first published online : 10 AUG 2015, DOI: 10.1002/hep.27960

  17. You have full text access to this OnlineOpen article
    All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

    Hepatology

    Volume 61, Issue 4, April 2015, Pages: 1127–1135, David R. Nelson, James N. Cooper, Jacob P. Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley F. Freilich, Ziad H. Younes, William Harlan, Reem Ghalib, Godson Oguchi, Paul J. Thuluvath, Grisell Ortiz-Lasanta, Mordechai Rabinovitz, David Bernstein, Michael Bennett, Trevor Hawkins, Natarajan Ravendhran, Aasim M. Sheikh, Peter Varunok, Kris V. Kowdley, Delphine Hennicken, Fiona McPhee, Khurram Rana, Eric A. Hughes and on behalf of the ALLY-3 Study Team

    Article first published online : 10 MAR 2015, DOI: 10.1002/hep.27726

  18. You have free access to this content
    Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus

    Journal of Pharmacy and Pharmacology

    Volume 66, Issue 12, December 2014, Pages: 1653–1666, Bryant B. Summers, Joshua W. F. Beavers and Olga M. Klibanov

    Article first published online : 31 AUG 2014, DOI: 10.1111/jphp.12294

  19. Hepatitis C virus drug resistance–associated substitutions: State of the art summary

    Hepatology

    Volume 62, Issue 5, November 2015, Pages: 1623–1632, Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot-Matias and Veronica Miller

    Article first published online : 30 JUL 2015, DOI: 10.1002/hep.27934

  20. Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study

    Hepatology

    Accepted manuscript online: 22 JAN 2016, Paul Kwo, Norman Gitlin, Ronald Nahass, David Bernstein, Kyle Etzkorn, Sergio Rojter, Eugene Schiff, Mitchell Davis, Peter Ruane, Ziad Younes, Ronald Kalmeijer, Rekha Sinha, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott and James Witek

    DOI: 10.1002/hep.28467